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Abstract
Background: During the chronic stage of Complex Regional Pain Syndrome (CRPS), impaired
microcirculation is related to increased vasoconstriction, tissue hypoxia, and metabolic tissue
acidosis in the affected limb. Several mechanisms may be responsible for the ischemia and pain in
chronic cold CPRS.
Discussion:  The diminished blood flow may be caused by either sympathetic dysfunction,
hypersensitivity to circulating catecholamines, or endothelial dysfunction. The pain may be of
neuropathic, inflammatory, nociceptive, or functional nature, or of mixed origin.
Summary: The origin of the pain should be the basis of the symptomatic therapy. Since the
difference in temperature between both hands fluctuates over time in cold CRPS, when in doubt,
the clinician should prioritize the patient's report of a persistent cold extremity over clinical tests
that show no difference. Future research should focus on developing easily applied methods for
clinical use to differentiate between central and peripheral blood flow regulation disorders in
individual patients.
Background
Complex Regional Pain Syndrome (CRPS) is a painful dis-
order that usually develops as a disproportionate conse-
quence of trauma. The disorder most commonly occurs in
the limbs, and is characterized by spontaneous pain, allo-
dynia and mechanical hyperalgesia, abnormal regulation
of blood flow and sweating, oedema of skin and subcuta-
neous tissues, movement disorders, and trophic changes
of skin, organs of the skin, and subcutaneous tissues [1,2].
Growing evidence indicates that CRPS is accompanied by
various abnormalities of the microvascular system,
including an increase in the number of capillaries [3,4],
endothelial swelling, and changes in the vessel luminal
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wall [5]. These impressive capillary changes range from
severely thickened basal membrane with intimal vacuoli-
zation, perivascular edema, and debris from pericytes
between the basal membrane layers, to necrosis [6,7].
Greatly thickened multi-laminated walls are also
observed, which considerably reduce the inner diameter
of the vessel [4,8]. Endothelial cells exhibit a shrunken
appearance and capillaries with only endothelial cell
debris in the lumina have been observed, while other cap-
illaries could be traced by the thickened basal membrane
only, lacking the presence of other cellular remnants [7].
In an autopsy study of the affected limbs of two patients,
we found an increased number of migrated endothelial
cells, as well as an increase of eNOS activity in distal der-
mis specimens, indicating that endothelial dysfunction
may play a role in chronic CRPS [9].
In the CRPS diagnostic criteria [10], a clear distinction is
made between two subtypes to reflect the absence or pres-
ence of evidence of peripheral nerve injury. However,
growing evidence of minor nerve lesions in CRPS [8,11]
indicates that this distinction may be artificial.
Although the debate regarding the pathophysiology is still
ongoing, the role of excessive regional inflammation,
peripheral sensitization of primary somatosensory affer-
ents, and central sensitization of spinal neurons is becom-
ing clear [1,2,12,13]. Recently, evidence was found for the
presence of oxidative stress in CRPS patients since they
exhibited increases in salivary and/or serum lipid peroxi-
dation products and antioxidants [14,15]. Also recently,
Eberle et al. were able to demonstrate differences between
warm and cold CRPS including differences in Quantita-
tive Sensory Testing: more prominent sensory loss in cold
CRPS and more mechanical hyperalgesia in warm CRPS
[16].
The signs and symptoms are related to these mechanisms.
Relating the clinical picture to the underlying pathophys-
iology might help determine the pharmacotherapeutic
approach for an individual patient [17].
The clinical picture of CRPS, especially the signs of auto-
nomic dysfunction, and the discovery by Leriche that sur-
gical sympathectomy dramatically improved pain in
CRPS supports the important role of the sympathetic
nervous system in CPRS etiology [18]. The sympathetic
vascular regulatory system in CRPS was extensively exam-
ined by Baron et al., who measured differences in blood
flow and skin temperature in patients with CRPS after a
cold and warm acclimatization period, respectively. The
results indicated that differences in skin temperature and
blood flow are not static descriptors, but dynamic values
mostly dependent on environmental temperature and
likely emotional stress [19]. After sympathectomy, in
three out of four patients with cold CRPS, the affected
limb was considerably warmer and blood flow was con-
siderably higher compared to the healthy side. After a few
weeks, however, skin temperature and perfusion slowly
diminished, and the affected hand became cold again.
Denervation supersensitivity due to complete sympathec-
tomy was thought to be the underlying mechanism of
these alterations [19,20]. Wasner et al. measured hand
temperature in CRPS patients and healthy control groups
while changing whole-body thermal stress using a ther-
mal suit [21]. Whole-body cooling appears to be the most
effective way to induce massive tonic activation of cutane-
ous vasoconstrictor neurons [22]. Three distinct vascular
regulation patterns were identified, related to the duration
of the disorder. Temperature and blood flow differences
between the two sides were dynamic and most prominent
at a high to medium level of vasoconstrictor activity [21].
As a result, impairments of thermoregulatory responses
should be considered only for diagnostic reasons [23,24].
In the acute phase of CRPS, the affected limb is usually
warmer than the contralateral limb due to cutaneous
vasodilation, and a functional inhibition of sympathetic
vasoconstrictor activity has been shown [21,25]. In this
phase, the thermoregulatory blood flow is increased, but
the nutritive skin blood flow is unaltered; these differ-
ences may be due to differences in regulatory mecha-
nisms. The smooth muscles in the arterioles of the
nutritive capillaries are controlled by local factors,
whereas the arterioles in the subpapillary plexus are pre-
dominantly sympathetically controlled [26,27].
After a so-called intermediate phase in which skin blood
flow and temperature differences appear to alternate
between warm and cold, a large number of patients show
a permanent decrease in blood flow and temperature [28]
despite the return of sympathetic vasoconstrictor activity
with the duration of the disease [25]. This decrease has
been attributed to an increased sensitivity to circulating
catecholamines, probably due to upregulation of adreno-
ceptors following the initial period of reduced sympa-
thetic input [21,26,29-31]. The decrease in blood flow in
the intermediate and cold phase occurs in both the ther-
moregulatory and the nutritive microcirculation [26].
As demonstrated by simultaneous testing of skin blood
flow and sweat in one CRPS patient, vascular abnormali-
ties may not solely be the result of a disturbance of the
autonomic nervous system. Although sudomotor activity
was greater on the affected side, implying higher sympa-
thetic nerve activity, basal blood flow was also greater on
the same side. These results suggest that one or more fac-
tors increase basal blood flow despite high sympathetic
nerve tone on the affected side [32]. Other mechanismsBMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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may also be involved in the pathophysiology of the vascu-
lar abnormalities. The demonstrated increase in vasocon-
striction, tissue hypoxia, metabolic acidosis [33,34] and
vascular permeability for macromolecules [35] may also
indicate endothelial dysfunction.
Several recent studies [36-40] have demonstrated altera-
tions in the central sensorimotor processing in CRPS
patients. Changes in the central nervous system [41] play
a very important role in the current conception of CRPS
pathophysiology as well as its treatment. This paper, how-
ever, concentrates on the central and peripheral mecha-
nisms responsible for vascular abnormalities and pain in
CRPS; furthermore, we suggest potential treatment
approaches for CPRS.
Discussion
Mediators of changes in blood flow
The endothelium, the largest organ of the body, releases
agents that regulate vasomotor function, trigger inflam-
matory processes and affect hemostasis in response to
shear stress and hormonal stimuli, such as vasoactive sub-
stances [42]. Blood pressure and blood flow is regulated
by the release of the vasodilators nitric oxide (NO) and
prostacyclin (PGI2), and the vasoconstrictor endothelin
(ET) [43].
NO is generated from the amino acid L-arginine by three
major isoforms of NO synthase, namely neuronal
(nNOS), inducible (iNOS), and endothelial (eNOS)
enzymes [44]. nNOS and eNOS are constitutively
expressed and activated by calcium entry into the cells;
iNOS is calcium independent, and its synthesis is induced
in inflammatory and other cell types by stimuli such as
endotoxin and proinflammatory cytokines [44]. NO dif-
fuses through the artery wall to the vascular smooth mus-
cle cells in the media, where it increases the activity of
guanylate cyclase and the concentration of cyclic guanos-
ine monophosphate (cGMP), thus relaxing the vascular
smooth muscle and leading to vasodilation [45]. PGI2,
which only plays a limited role as a vasodilator in most
vascular beds, is produced from arachidonic acid by
cyclooxygenase in response to shear stress and a number
of factors that also increase NO production. PGI2 activates
adenylate cyclase to increase cyclic adenosine monophos-
phate (cAMP), also leading to vasodilation [46,47].
The peptide ET, one of the most potent known vasocon-
strictors, is generated by cleavage of a large polypeptide
within the endothelium. Of the three types of ET, ET-1 is
the most important in vascular tissue, and it acts on
endothelin-A receptors on the vascular smooth muscle
[48]. Evidence suggests a feedback mechanism between
ET and NO, as ET inhibits the production of NO, while
NO inhibits ET production [44,47,49,50]. The major bio-
logical effects of these vasoactive substances depend on
their rapid synthesis. The maximal NO stimulation can be
reached within seconds, but the maximal vasoconstrictive
response of endothelium in vivo takes up to one hour [51].
Vasomotor tone is regulated by ET-1 and NO, depending
on the health of the endothelium [51,52].
Endothelial dysfunction
Endothelial dysfunction (EtD) was first described by
Panza as an impairment of the regulation of endothelium
on blood vessels [53]. As a proinflammatory and pro-
thrombic state, EtD has been described in the pathophys-
iology of different forms of cardiovascular disease,
including hypertension, coronary artery disease, chronic
heart failure, peripheral artery disease, diabetes, and
chronic renal failure [42]. Under these conditions, the lev-
els of pro-oxidant reactive oxygen species in the vessel
wall are elevated. NO is rapidly degraded by oxidant stress
and the vasoinactive and toxic peroxynitrite is produced.
In both animal and human studies, this process could be
prevented by administration of high concentrations of the
antioxidant vitamin C [51,54,55].
Flow mediated dilation (FMD) is an important tool for
assessment of endothelial function both in the upper [56]
and the lower [57] limb. In vivo, endothelial function may
be assessed invasively on resistance arteries by measuring
blood flow using strain-gauge plethysmography by study-
ing the effects of acetylcholine or metacholine administra-
tion through an intra-arterial catheter [58]. Acetylcholine
has a direct vasoconstrictive effect on vascular smooth
muscles. However, NO from activated healthy endothe-
lium overwhelms the direct effect of acetylcholine, which
results in vasodilation. This vasodilation is blocked by
inhibitors of NO synthesis, such as monomethylarginine.
In endothelial dysfunction, less NO is generated, which
may ultimately lead to a vasoconstrictive response to ace-
tylcholine [51,59,60]. Shear stress, which stimulates the
endothelium to release NO, may be used to non-inva-
sively induce reactive hyperaemia, and the subsequent
changes in blood flow can be measured by ultrasound.
This has been shown in the brachial artery using FMD
[61]. Other non-invasive in vivo techniques include finger-
tip pulse wave amplitude with peripheral arterial tonom-
etry [62], measurement of intima-media thickness [63],
and flow waveform patterns [64]. In vitro, the endothelial
dysfunction of isolated resistance arteries dissected from
biopsies of gluteal subcutaneous tissue has been studied
on a wire or pressurized myograph. A good correlation
was found between the endothelial function of small
arteries in vitro and FMD of the brachial artery in vivo
[42,65].
Several studies have assessed the microvascular endothe-
lial function in CRPS patients with controversial results.BMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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Gorodkin et al. used iontophoresis to test endothelial
dependent vasodilation with acetylcholine and endothe-
lial independent vasodilation with sodium nitroprusside
in 17 CRPS patients and 16 healthy controls. Among the
CRPS patients (IASP criteria) 4 were qualified as warm
and 13 as cold; the median duration of the symptoms was
5 years (range 3 months to 20 years). No significant differ-
ences were observed between both groups or between
affected and unaffected limbs [66].
However, these results could not be reproduced by
Schattschneider et al., who compared 14 patients with
cold CRPS (disease duration 17.6 ± 2.1 months) with 10
healthy controls. In this study, acetylcholine induced
vasodilation was significantly reduced on the affected side
compared to the contralateral extremity and controls,
whereas no differences were observed after application of
sodium nitroprusside [67].
Similar results were found in a study by Duman et al., who
used the FMD technique to examine 21 patients in a more
acute stage of CRPS (IASP criteria, disease duration 5.9 ±
2.5 months), and compared the results with 15 healthy
controls. Upon evaluation of the brachial artery with
Doppler ultrasound, significant differences were observed
in the waveforms obtained in the affected compared to
contralateral limbs; although not significant, there was a
trend of larger dilating responses in the affected limbs
[64].
In a small study with 9 patients with CRPS in one upper
limb and 9 patients with CRPS in a lower limb, Dayan et
al. examined FMD and local vascular reflexes [68]. To
measure the venoarteriolar reflex (VAR), a cuff is inflated
to a steady pressure of 40 mm Hg for 4 minutes to pro-
duce venous congestion, which causes a reflexive regional
arteriolar vasoconstriction. To measure the microvascular
myogenic reflex (VMR), the subject is placed in supine
position to avoid systemic baroreflex changes and the leg
or forearm is measured during 40 cm dependency of the
leg or forearm below cardiac level for 4 minutes. This acti-
vates the myogenic response by increasing the arterial wall
pressure, and the venoarteriolar response by gravitation-
ally increasing the venous pressure. The result is local
vasoconstriction and, consequently, a reduced blood
flow. The duration of the disease was 40 and 46 months
for upper and lower limb CRPS, respectively, which was
diagnosed using the IASP criteria. In comparing the
affected limb to the contralateral side, the resistance artery
FMD was impaired on the CRPS side along with exagger-
ated arteriolar vasoconstriction following activation of the
VAR, while the VMR remained unchanged. These changes
in vascular reflexes were only significant in the lower
limbs. The VAR depends mostly upon intact local auto-
nomic nervous functions, but the VMR is an inherent arte-
riolar muscle constriction reflex in response to dilation,
which appears to be independent of neural transmission.
Based on these observations, the authors concluded that
the impaired VAR and intact VMR might reflect the adren-
ergic hypersensitivity in the lower limbs in patients with
CRPS [68].
The results from these four studies suggest that changes in
vascular response are found locally only at the side
affected by CRPS, while there is no difference between the
contralateral side and healthy controls. Whether there is a
relation between stage of the disease (warm, intermediate
or cold) or the duration of the disease, and endothelial
dysfunction is not yet clear. In discussing the first three tri-
als, Duman [64] suggested that symptoms of vascular
changes, such as hyperemia and edema, may lose their
prominence in chronic CRPS, whereas they may be more
evident in earlier stages. On the other hand, the study by
Dayan in a group of patients with longer disease duration
showed clear differences. No significant differences in
blood flow were found between CRPS side, unaffected
side or healthy controls at baseline. This is another indica-
tion that the regulatory mechanisms in particular are
affected in vascular alterations in CRPS. The same conclu-
sion was previously made by Wasner [21], who studied
the sympathetic regulation mechanism in the hands of
CRPS patients by inducing temperature changes to the
entire body with a thermal suit; they concluded that the
differences in blood flow and temperature were not static.
No significant differences were detectable during low or
absent sympathetic vasoconstrictor activity, and these dif-
ferences were most pronounced during periods of inter-
mediate to high sympathetic activity [21].
In addition to changes in the somatosensory systems,
which process noxious, tactile and thermal information,
and changes to the sympathetic systems, which innervate
skin and somatomotor systems, peripheral changes are
detected in CRPS that cannot be explained by the central
changes [1]. These peripheral changes (sympathetic affer-
ent coupling, vascular changes, inflammatory changes,
edema, and trophic changes) cannot be seen independent
of the central changes [1,69]. Furthermore, each symptom
can also be generated by more than one mechanism,
depending on the patient. Therefore, caution must be
taken when grouping patients based on symptoms and
administering drugs irrespective of their underlying dis-
ease [1]. A cold extremity in chronic CRPS could be caused
by several factors, such as increased tone of the sympa-
thetic nervous system, pathologic alterations of the vascu-
lar wall, changes in small nerve fibers innervating the
blood vessels, or endothelial dysfunction. It is also possi-
ble that as symptoms of endothelial injury progress, there
may be a shift from a predominant oedema associated
with plasma extravasation from damaged post-capillaryBMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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venules (an early consequence of endothelial injury) to
chronic ischemia with the development of arterial vasos-
pasms and capillary no-reflow (later consequences of
endothelial injury). Furthermore, sympathetic blocks or
the use of vasodilatory agents may overcome ischemia
that is dependent on arterial vasospasms, which repre-
sents a functional reduction in blood flow; this, however,
would not be able to overcome ischemia associated with
capillary no-reflow, which represents a physical reduction
in blood flow. These observations may explain why the
results of trials studying medication to improve blood
flow in patients with cold chronic CRPS do not show
more convincing results. It may also explain, why an inter-
vention to improve blood flow does not improve pain in
all patients alike.
Pain
Pain is an important symptom in CRPS. Most patients
experience an intense, spontaneous, burning pain in the
distal part of the affected limb, which is characteristically
disproportionate in intensity to the initial event, and
increases in a dependent position [1]. Several types of
pain can be distinguished: neuropathic, inflammatory,
nociceptive and functional [70]. Evidence supports a neu-
ropathic origin of the pain in CRPS [71]. The spatial dis-
tribution of pain and sensory abnormalities such as
allodynia to mechanical, cold and heat stimuli, as well as
hyperalgesia, indicate that the pathophysiological mecha-
nisms in CRPS involve both the peripheral and central
nervous system [1,72,73], but the interaction between the
peripheral and central changes is only partially under-
stood [71].
The various mechanisms by which pain is generated in
CRPS are outlined below. The section on ischemic pain is
of particular relevance to this discussion, as it closely
relates to changes in peripheral blood flow.
Neuropathic pain
The neuropathic pain in peripheral tissues may be gener-
ated and maintained by peripheral sensory nerve fibers.
Quantitative sensory testing studies strongly suggests a
role of peripheral inflammation in acute CRPS, and a loss
of small fibres in acute as well as chronic CRPS. Acute
CRPS patients demonstrated heat pain hyperalgesia, while
chronic CRPS (>12 months) showed warm as a well as
cold hypoesthesia [40]. Oaklander et al. analyzed the
innervation density of the epidermis, and their results sug-
gest that CRPS is especially associated with persistent min-
imal distal nerve injury affecting nociceptive small fibers,
a type of nerve injury that will remain undetected in most
clinical settings [11]. Albrecht studied the innervation of
CRPS affected skin tissue, and found impressive changes
in innervation of different target tissues as well as changes
of the target tissue itself (e.g. blood vessels) [8]. Although
the results of these two studies must be interpreted with
care, as these observations may be the result of secondary
tissue changes that may occur in the course of the disease,
both studies indicate that CRPS can be associated with
peripheral pathological changes of innervation of the
skin, thus CRPS may indeed be a neuropathic pain syn-
drome [8,11,71]. Neuropathic pain may also be caused by
aberrant activity of the sympathetic nervous system (SNS),
in which case the pain is referred to as sympathetically
maintained pain (SMP) [72,74]. In patients with SMP,
sympathetic blockade relieves spontaneous pain and
mechanical hyperalgesia, but these symptoms may reap-
pear following intracutaneous application of noradrena-
line [19,75,76] or by stimulation of the SNS by cooling of
the body or forehead, or a startle stimulus [77,78]. SMP is
not typically observed in CRPS; only 50% of CRPS
patients experience SMP [79-81], and a number of neuro-
pathic pain syndromes might also benefit from sympa-
thetic blocks [30,72]. It should be noted, that the
Cochrane analysis states that 'no conclusion concerning
the effectiveness of sympathetic blocks could be drawn'
[82].
Inflammatory Pain
Sudeck was the first to describe the classic signs and symp-
toms of inflammation, including rubor, calor, dolor,
tumor and function laesa, in acute CRPS [83,84]. Kozin
[85] described inflammatory changes in 2 patients with
early CRPS, and Oyen [35] found increased vascular per-
meability for macromolecules, which was thought to be
due to the inflammatory response, caused by free oxygen
radicals. Increased systemic calcitonin gene-related pep-
tide (CGRP) serum concentrations were found by Birklein
[86], suggesting neurogenic inflammation as the patho-
physiologic mechanism. In this study, however, pain and
hyperalgesia were observed in chronic stages in particular,
independent of the increased neuropeptide concentra-
tion.
Our research group compared levels of proinflammatory
cytokines tumor necrosis factor alpha (TNF-α) and inter-
leukin 6 (IL-6) in plasma and fluids of artificially induced
blisters on the CRPS side and contralateral side. There was
no indication for inflammation in plasma [12], which
was confirmed by van de Beek [87]. However, Huygen et
al. demonstrated that TNF-α and IL-6 levels were
increased in blister fluids in patients with acute CRPS
[12]. This shift in the pro-inflammatory cytokine profile
in acute CRPS patients was also found by Uceyler [2].
In three studies of patients with an intermediate disease
duration of 2.5, 2.8 and 3.5 years, the levels of these
cytokines were still increased [88-90]. Remarkably, a large
proportion of these patients no longer displayed any of
the above-mentioned signs and symptoms of inflamma-BMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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tion. A study of chronic CRPS patients with a disease dura-
tion of 6 years showed no differences in TNF-α and IL-6,
although some patients still showed signs of inflamma-
tion [91]. No relationship between pro-inflammatory
cytokines and disease characteristics, such as pain,
changes in temperature, volume, mobility and disease
duration, was observed in either study [88,91].
Ischemic pain
In rats, during the reperfusion which follows prolonged
extremity ischemia, the synthesis of free radicals and pro-
inflammatory cytokines leads to inflammatory responses
and vasculature injury in the ischemic tissue [92]. This
ischemia-reperfusion causes damage to the endothelial
cells, resulting in swelling and protrusion of cells in the
capillary lumen with impeded passage of red blood cells
as consequence, the so-called slow-flow/no-reflow phe-
nomenon. Coderre also showed that ischemia-reper-
fusion of the rat hind paw induced long-term mechanical
and cold hypersensitivity, which was effectively reduced
by free radical scavengers [93] as well as classical analge-
sics, although to a lesser extent [94]. These symptoms are
comparable to those described in humans with CRPS.
Recently, Coderre and colleagues also showed that
mechanical allodynia induced by hind paw ischemia-
reperfusion injury is accompanied by increased hind paw
muscle malondialdehyde (a product of free radical-
induced lipid peroxidation), pro-inflammatory cytokines
(IL-1β, IL-6 and TNFα), nuclear factor κB and lactate; fur-
thermore, mechanical allodynia is reduced by inhibitors
of these mediators or an antagonist at acid sensing ion
channels (ASICs) [95]. The authors also demonstrated
that mechanical allodynia following ischemia-reper-
fusion injury parallels the development of arterial vasos-
pasms, endothelial cell thickening and capillary slow-
flow/no-reflow in hind paw muscle, and is directly corre-
lated with muscle lactate but not with the demonstrated
reduction in intraepidermal nerve fibers [95,96]. Further-
more, similar to CRPS patients, rats with hind paw
ischemia-reperfusion injuries exhibit enhanced pain and
allodynia following exercise, symptoms that depend on
increases in muscle lactate [95].
In human patients treatment with free radical scavengers
can both reduce the risk of developing CRPS [97-100] and
improve the clinical picture [66,101-103]. This observa-
tion was supported by recent evidence of increased levels
of saliva and serum antioxidants and serum malondialde-
hyde in CRPS patients [14], which is almost definitive
proof for the involvement of free radicals in the patho-
physiology.
Regardless of the initial pathogenesis, one hypothesis has
proposed a vicious circle of altered blood flow that leads
to hypoxia, production of free radicals, endothelial dam-
age and further reductions in blood flow [66]. The slow-
flow/no-reflow injury may even affect the microvascula-
ture of peripheral nerves, thus presenting the cause of
peripheral neuroinflammation in CRPS [15].
Nociceptive pain
One of the characteristics of CRPS is the often observed
disproportionate severity of the symptoms with the sever-
ity of the trauma, along with a tendency to generalize in
the affected distal limb but not confined to the innerva-
tion zone of an individual nerve [30]. Nociceptive pain
may be caused by tissue damage as a result of the initiating
trauma or by secondary tissue changes that occur in the
course of the disease, i.e. oedema, changes in the nutritive
blood flow, hypoxia, lactate increase and acidosis
[33,34,71,104-106].
Functional pain
Functional pain is defined as hypersensitivity to pain
resulting from abnormal central processing of normal
input [70]. CRPS patients are known to protect their
involved limb to minimize pain associated with move-
ment and touching; this protection has been described as
a voluntary action, but lately neglect-like behavior has
been proposed to play an important role. Two terms have
been introduced in describing this behavior: 'cognitive
neglect', which suggests that patients perceive their
involved limb as feeling foreign to them, and 'motor
neglect', which describes situations in which the patients
need to focus mental and visual attention to move their
limb [107]. In a survey of 224 CRPS patients, 84% of the
respondents confirmed the presence of at least one of
these neglect symptoms, and 47% indicated they experi-
enced both [107]. Other studies also found a large propor-
tion of CRPS patients with disturbances of self-perception
of hand or foot, indicating an alteration in the processing
of the higher central nervous system [108-110].
Disuse has often been mentioned in CRPS. In animal
studies of immobilization, an increased sensitivity to sen-
sory stimuli, as well as changes at the spinal level that
could account for this increase, have been found [111-
113]. In humans, casting produced increased cerebral
blood flow in areas associated with sensory processing,
motor function, and emotions [112,114]. These studies
indicate that immobility alone may produce many signs
and symptoms also found in patients with CRPS [112].
Fear of injury has also been suggested as a potential pre-
dictor of disability in CRPS [115], and combined with
increased sensitivity for pain, fear of injury may lead to
excessive guarding and over-protective behaviors [116].
Rommel et al. found that depressive syndromes fre-
quently develop with chronic CRPS, and psychological
treatment can be recommended [117]. Nevertheless,
despite the often suggested relationship between CRPSBMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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and a psychological predisposition, Van de Laan et al.
used the SCL 90 and did not find any specific psychologi-
cal profiles in CRPS-dystonia [118]. In a large population-
based study, De Mos et al. also did not find any relation-
ship between pre-existing psychiatric disorders and CRPS
(odds ratio of 1.17) [119].
Pharmalogical interventions
We investigated the involvement of the vasoactive sub-
stances ET and NO during early chronic CRPS. Measure-
ment of NO and ET levels in artificial suction blisters in 29
patients showed a significant increase in ET and a decrease
of NO on the affected side compared to the unaffected
side, indicating an aberrant NO/ET ratio in the intermedi-
ate state of CRPS. This altered ratio results in vasoconstric-
tion and consequently in diminished tissue blood
distribution [89]. The ratio could be restored by the sub-
stitution of NO, substitution of asymmetric dimethyl-
arginine (ADMA) [120], or the blocking of ETA receptors
[49]. As several recent publications indicate that NO sub-
stitution might be valuable in treating diabetic neuropa-
thy [121], anal fissures [122,123], and epicondylitis
[124], we propose that the effective treatment of CRPS by
NO substitution, which was shown previously [125],
occurs by increasing blood flow. In a pilot study, five
female patients with cold type CRPS in one hand were
treated with NO donor isosorbide dinitrate (ISDN) oint-
ment 4 times daily for 10 weeks; videothermography was
used to monitor changes in blood distribution in both the
involved and contralateral extremities. The patients
treated with ISDN showed a 4-6°C increase in mean skin
temperature of the cold CRPS hands, reaching tempera-
tures similar to that of contralateral extremities within 2-
4 weeks, suggesting normalization of blood distribution;
normalization was confirmed by an improvement in skin
color. In three patients, the VAS pain declined, whereas in
the other two patients, the VAS pain remained unchanged.
Thus, the topical application of ISDN appeared to be ben-
eficial in improving symptoms for patients with cold type
CRPS [126].
Based on these preliminary results, we decided to test the
effect of ISDN in a double blind randomized controlled
trial. Twenty-four patients with chronic CRPS in one
upper extremity received 1% ISDN in Vaseline or a pla-
cebo ointment applied to the dorsum of the affected hand
4 times daily for 10 weeks. The patients participated in a
physical therapy program to improve activity. The primary
outcome measure was blood distribution in the affected
extremity, which was determined by measuring the skin
temperature using videothermography. We also measured
NO and ET-1 concentrations in blister fluid, assessed pain
using the VAS, and determined activity limitations using
an Upper Limb Activity Monitor (ULAM) and the Disabil-
ities of Arm Shoulder and Hand Questionnaire (DASH).
ISDN failed to produce a significant improvement in tem-
perature asymmetry in chronic cold CRPS patients, and
also did not generate the predicted reduction in pain and
increase in activity compared to placebo. The results of the
active treatment group are shown in Figure 1. Together
this suggests that other central or peripheral factors may
contribute to the disturbed vasodynamics in cold chronic
CRPS that are not influenced by NO substitution [127].
To further evaluate the influence of endothelial factors,
patients with chronic cold CRPS in one lower extremity
were included in a double blind, randomized, controlled
trial that investigated the effect of tadalafil on the micro-
circulation. Tadalafil, a PDE-5-inhibitor known as an
effective treatment for erectile dysfunction [128], func-
tions within the vascular smooth muscle cell to inhibit the
hydrolyzation of cyclic guanosine monophosphate
(cGMP) to GMP. Through the phosphorylation of specific
proteins and ion channels, treatment with tadalafil results
in the opening of potassium channels and hyperpolariza-
tion of the muscle cell membrane, sequestration of intra-
cellular calcium by the endoplasmic reticulum, and block
of calcium influx by the inhibition of calcium channels.
The consequence is a drop in cytosolic calcium concentra-
tions and relaxation of the smooth muscle that causes
vasodilation [128]. In this trial, twenty-four patients
received 20 mg tadalafil or placebo daily for 12 weeks,
and participated in a physical therapy program. The pri-
mary outcome measure was temperature difference
between the CRPS and the contralateral sides, as deter-
mined by measuring the skin temperature with videother-
mography. Secondary outcomes were pain measured on a
VAS, muscle force measured with a MicroFet 2 dynamom-
eter, and level of activity measured with an Activity Mon-
itor (AM) and walking tests. At the end of the study
period, the temperature asymmetry was not significantly
reduced in the tadalafil group compared with the placebo
group, but there was a significant and clinically relevant
reduction of pain in the tadalafil group. Muscle force
improved in both treatment groups, and the AM revealed
small, non-significant improvements in time spent stand-
ing and walking, as well as the number of short walking
periods. The results of the active treatment group are also
shown in Figure 1. Thus, tadalafil may be a promising new
treatment for patients with chronic cold CRPS. The use of
tadalafil and the role of endothelial dysfunction in CRPS
warrants further investigation [129].
In both studies, the results of treatment with study medi-
cation was compared to placebo, and, as shown in Figure
1, there were clear responders and non-responders among
the patients that received the active medication in both
studies.BMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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The results of the static videothermographic measure-
ments should be interpreted with care, due to the dynamic
nature of side temperature differences in CRPS
[19,21,130,131]. Long-term skin temperature measure-
ments may prove to be a more reliable instrument for
determining temperature changes in CRPS [132]. Further-
more, care should be taken when using the clinically unaf-
fected side as a control for studies on thermoregulatory
skin blood flow in the CRPS side. One possibility is that
the thermoregulatory skin blood flow in both extremities
may have resulted from a spinal reflex mechanism initi-
ated by (post-) traumatic excitation of a peripheral nerve
on the clinically affected side [133]. Given the pathology
of muscle tissue (including lipofuscin deposits, atrophic
fibers, and severely thickened capillary basal membranes)
observed in the amputated limbs of CRSP patients as
described by van der Laan et al. [7], as well as the role of
muscle pathology (increased lipid peroxidation products,
pro-inflammatory cytokines and lactate) in mechanical
allodynia of rats with ischemia-reperfusion injury, altera-
tions in deep tissue blood flow, as well as skin blood flow,
may be important in CRPS. Also, since capillary hemo-
globin oxygenation (HbO2) is lowered and skin lactate is
increased in CRPS limbs, alterations in nutritive as well as
thermoregulatory blood flow may also be important in
CRPS.
Recent evidence suggests that both NO and ET also play a
role in nociception exhibited in animals with ischemia-
reperfusion injuries. The mechanical allodynia that is
observed in rats with a hind paw ischemia-reperfusion
injury is relieved by systemic administration of the NO
donor 3-morpholinylsydnoneimine chloride (SIN-1)
[96]. Furthermore, intradermal injections of either nore-
pinephrine or the endothelial NO synthase inhibitor N5-
(1-Iminoethyl)-L-ornithine dihydrochloride (L-NIO)
(both of which should reduce blood flow) induce sus-
tained nociceptive behaviours in rats with hind paw
ischemia-reperfusion injuries; the nociceptive behaviours
induced by NE are reduced by local or systemic adminis-
tration of the NO donors sodium nitroprusside and SIN-
1, respectively [96]. This observation raises the possibility
that sympathetically maintained pain may depend more
on NE-induced vasoconstriction than on sympathetic-
afferent coupling. This conclusion is supported by the
finding that sustained nociceptive behaviours are also
induced in rats with hind paw ischemia reperfusion inju-
ries after intradermal injection of the non-adrenergic
Relationships between the improvements in temperature and pain in the ISDN and Tadalafil studies Figure 1
Relationships between the improvements in temperature and pain in the ISDN and Tadalafil studies. The 
improvement in pain is shown on the horizontal axis. The Visual Analogue Scale (VAS, score 0-100) is the average of actual pain 
scores that were recorded three times each day (0800, 1200 and 2000) during one week before the first and the last hospital 
visits. The improvement in pain is calculated by subtracting the VAS score at the end of the study from the VAS score at the 
start of the study; thus, a positive value indicates less pain. The vertical axis shows the changes in temperature calculated by 
subtracting the temperature difference (CRPS side minus contralateral side) between the dorsal side of both hands at the end 
of the study from the difference measured at the start of the study. A positive value indicates that the difference in tempera-
ture has diminished.BMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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vasoconstrictor vasopressin [96]. Coderre and colleagues
recently demonstrated that mice with ischemia-reper-
fusion injury of the hind paw exhibit sustained nocicep-
tive behaviors following intradermal injection of ET-1 or
ET-2. These nociceptive behaviours correlated with
increased ET-A receptor expression in hind paw muscle,
and were reduced by co-administration of an ET-A antag-
onist (T. Coderre, personal communication).
Treatment strategies for endothelial dysfunction in CRPS
patients include the substitution of nitric oxide with
ISDN, inhibition of PDE5, substitution of ADMA, or
blockage of ETA receptors. Of these strategies, only ISDN
and PDE5 inhibition have been tested in randomized pla-
cebo-controlled trials with CRPS patients. Because these
trials included patients with cold chronic CRPS and did
not differentiate between central and peripheral dysfunc-
tion, the results may not be conclusive for the treatment
of endothelial dysfunction.
Calcium antagonists are used in the treatment of hyper-
tension and angina pectoris, as they bind to the L-type cal-
cium channel in the smooth muscles of the vascular wall,
thus reducing the influx of extracellular calcium and
resulting in vasodilation. Nifedepine has been examined
in two descriptive studies with CRPS patients, and this cal-
cium antagonist was most effective in acute CRPS
[134,135]. In two studies performed by our research
group, only a few patients used the calcium antagonist
verapamil and none used nifedepine. In addition to
peripheral vasodilation, verapamil also causes a reduction
of the heart rate and atrioventricular conduction. Since
nifedepine is a more potent peripheral vasodilator with
only minimal cardiac side-effects [136], one of the long-
acting dihydropyridines such as nifedipine might prove
advantageous in cold chronic CRPS [137]. More research
on this subject is warranted.
An interesting development occurred in the tadalafil
study, when one patient who had not responded to the
active tadalafil treatment with an increase of temperature
and showed persistent high pain scores was treated with a
lumbal sympathectomy. The leg on the CRPS side became
warmer, and the temperature increased until it was more
than 1°C warmer than the contralateral side. This
improvement in temperature (difference) still persists. We
consider this an indication that in cold chronic CRPS,
both endothelial dysfunction and sympathetic dysfunc-
tion may be responsible for ischemia in the cold extrem-
ity. Unfortunately, in this patient, the severe pain was
unaffected by the sympathectomy, indicating that in
CRPS, pain and ischemia may be related in some cases,
but an increase in blood flow will not result in less pain in
other cases.
This observation confirms the result of trials performed by
Baron et al. in analyzing skin blood flow demonstrating
that sympathetic vasoconstrictor reflexes and pain after
surgical sympathectomy show no clear relationship of
vascular changes and the success of sympathectomy
regarding pain relief [19]. Thus, apart from nociceptive
and neuropathic pain, pain in chronic cold CRPS may
also be due to ischemic pain caused by endothelial dys-
function [67,73,93], sympathetic hyperactivity or
increased sensibility to circulating catecholamines [20], or
sympathetically maintained pain [77].
In a study with intermediate CRPS patients (disease dura-
tion 2.8 ± 1.4 years), we found a significant increase in IL-
6, TNF-α and ET-1 levels in blister fluid in the CRPS
extremity versus the contralateral extremity [89]. ET-1
concentrations in the cold chronic patients in the ISDN
study were lower than those in our previous study, but
still higher than levels previously reported by others
[127,138,139]. Apparently, some of these chronic cold
patients still had active inflammatory components, which
may explain the case of one of the outpatients who was
treated with a PDE5-inhibitor for a very cold painful foot
in chronic CRPS. In a few days, the affected foot displayed
full-blown warm CRPS. The classical signs of inflamma-
tion (rubor, calor, dolor, tumor and functio laesa) depend
highly on unimpaired circulation. Similar to the implica-
tions of the ET-1 measurements of the ISDN study, this
case suggests that there may be patients with chronic cold
CRPS with active inflammation who do not show symp-
toms of inflammation because of impaired vasodilation.
Indeed, it has been shown that plasma extravasation does
not occur in the later stages of ischemia-reperfusion injury
after the development of no-reflow. Thus, oedema only
occurs with leakage of plasma from the post-capillary
venules of vessels that are adequately perfused [140]. This
may account for persistent pain and other therapy-resist-
ant symptoms in some patients.
Current research in the field suggests several possible
mechanisms responsible for ischemia and pain in chronic
cold CRPS. Because of the fluctuation of temperature dif-
ference between both hands, even a patient who reports
an extremely cold extremity may present no difference in
temperature in the clinic or even a warmer CRPS side. In
this case, a static video thermographic recording may not
show any difference compared to a manual test. Under cir-
cumstances of doubt, the clinician should let the patient's
report of a persistent cold extremity prevail over clinical
tests that show no difference.
Several tests have been described to separately investigate
the sympathetic and the endothelial function. Until now,
these tests have only been used for research purposes.
Promising results were found using provocative manoeu-BMC Musculoskeletal Disorders 2009, 10:116 http://www.biomedcentral.com/1471-2474/10/116
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vres, like the Valsalva manoeuvre, and the cold pressor test
[141], or inspiratory gasp and contralateral cooling
[19,142,143].
Future research should focus on methods to differentiate
between sympathetic and endothelial dysfunction for
clinical use. Laser Doppler Flow, video thermographic
recordings and ultrasound could be used to measure the
results of autonomic provocation tests, and flow mediated
dilation, in combination with long-term temperature
measurements. Investigators should not only focus on
blood flow in the skin but also in deep tissues; more infor-
mation is needed regarding the separate contributions of
thermoregulatory and nutritive blood flow.
To differentiate between sympathetically maintained pain
(SMP) and sympathetically independent pain (SIP), a
sympathetic block has been advised [76], usually indicat-
ing an invasive chemical or a surgical block [144-147].
Bolel et al., however, described a non-invasive stellate
ganglion blockade using diadynamic current [148] that
could provide a simple and easy to perform method to
differentiate between SMP and SIP.
Summary
As a result of an impressive amount of research over the
last few years, our understanding of CRPS has improved
considerably. Although some studies have suggested that
CRPS is primarily a disease of the central nervous system,
alterations have also been found in the peripheral small
nerve fibers innervating skin, blood vessels and sweat
glands, as well as aberrations in the vascular wall, muscle
fibers and other deep somatic tissues, likely as a result of
damage by the initial inflammation. Although this article
focused on disturbed peripheral blood flow in patients
with cold, chronic CRPS, treatment goals are not necessar-
ily only local. In this respect, we agree with Harden, who
proposes that the treatment of CRPS should be a system-
atic and coordinated interdisciplinary approach with a
primary goal of functional restoration [69].
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